TOPICAL ASPECTS OF MODERN RADIATION ONCOLOGY
To the 65th anniversary of its foundation of R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine
DOI:
https://doi.org/10.15407/oncology.2025.02.152Keywords:
therapeutic irradiation, post-radiation complications, repair, toxicity, radiomodifiersAbstract
It has been established that radiation therapy along with devitalization of malignant neoplasms increases the risk of post-radiation complications from radio-vulnerable tissues and organs. Therefore, minimizing the frequency and severity of these complications after RT courses without compromising its effectiveness remains a pressing issue in modern oncology. An effective approach to treating oncogynecological patients is the introduction of chemotherapy in combination with RT into clinical practice. It is known that cellular DNA repair systems aimed at preserving and stabilizing the integrity of the genome counteract the death of neoplastic cells and thereby reduce the effectiveness of tumor radiation therapy. The author of this work proposed a new approach to improving cancer prevention aimed at reducing the risk of post-radiation complications. The main goal of the proposed methodology for tertiary cancer prevention is to increase the radioresistance of tissues surrounding the tumor. The article is aimed for the professionals who work in experimental and applied areas of radiobiology, oncology, radiation medicine and others.
References
Solodkiy VB. Results of radiation therapy for invasive cervical cancer. Radiation and risk 2023; 32 (3): 6–17. https://doi. org/10.21870/0131-3878-2023-32-3-122-133.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021: 71: 209–49. https://doi.org/10.3322/caac.21660.
Chrysostomou AC, Stylianou DC, Constantinidou A, Kost- rikis LG. Cervical cancer screening programs in Europe: Based HPV testing. Viruses 2018; 10 (12): 729. https://doi. org/10.3390/v10120729.
Lei J, Ploner A, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 2020; 383 (14): 1340–8. https://doi.org/10.1056/NEJMoa1917338.
Zavyalov AA, Solodova AN, Tyryshkin AI, Kryakvina EV. Brachytherapy of malignant neoplasms of the cervix uteri: Current status of the problem (literature review). Med Radiol Radiat Safety 2023; 68 (6): 99–105. https://doi. org/10.33266/1024-6177-2023-68-6-99-105.
Domina E, Philchenkov A, Dubrovska A. Individual response to ionizing radiation and personalized radiotherapy. Crit Rev Oncog 2018; 23 (1–2): 69–92. https://doi.org/10.1615/ Crit Rev Oncog. 2018026308.
Domina EA. Radiogenic cancer: epidemiology and primary prevention. Kyiv: Naukova Dumka, 2016. 196 p. ISBN 978-966-00-1525-8.
Domina E, et al. Radiation cytogenetics. Kyiv: Zdorovya, 2009. 368 p. ISBN 978-966-463-014-3.
Cytogenetic dosimetry: Applications in preparedness for and response to radiation emergencies. Vienna: IAEA, 2011. 232 p.
Vishnevskaya TV, Isubakova DS, Tsyplenkova MYu, et al. Comparative retrospective analysis of the results of cyto- genetic studies of employees of the object of use of ionizing radiation. Medical radiology and radiation safety 2024; 69 (1): 61–6. https://doi.org/10.33266/1024-6177-2024-69- 1-61-66.
Gaziiev AI. On the prospects of using the DNA repair inhibi- tors in radiotherapy of tumors. Radiation biology, radio- ecology 2014; 54 (3): 229–40.
Joiner M, Kogel A. Basic clinical radiobiology. 5th edn. Boca Raton, FL: CRC Press/Taylor & Francis Group; 2019. 350 p.
Gregoire O, Hittelman W, Rosier JF, et al. Chemoradio- therapy: radiosensitiving nucleoside analogues. Oncol Rep 1999, 6: 949–57.
Altana R, Liang X, Yu JJ, Reed E. Excision repair cross complementing — group 1: gene expression and platinum resistance. Int J Mol Med 2004; 14 (6): 959–70.
Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA- PK inhibition by NU 7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res Treat 2014; 143 (1): 47–55. https://doi.org/10.1007/s10549-013-2785-6.
Chow JP, Man WY, Mao M, et al. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol Cancer Ther 2013; 12 (11): 2517–28. https://doi.org/10.1158/1535-7163.MCT-13-0010.
Grinevich YuA, Domina EA. Immune and cytogenetic effects of dense and rare ionizing radiation. Kyiv: VD "Aicena", 2021. 384 p.
Peters S, Portengen L, Bonassi S, et al. Intra- and interindi- vidual variability in lymphocyte chromosomal aberrations: implications for cancer risk assessment. Am J Epidemiol 2011; 174 (4): 490–3. https://doi.org/10.1093/aje/kwr114.
Domina EA, Dumansky YuV. Medical and radiobologycal aspects of radiaton complications in patents with onco- gineacological profile. Oncology 2023; 25 (1): 9–15. https:// doi.org/10.15407/oncology.2023.01.009.
Domina EA. Modern view on the problem of radiation car- cinogenesis. Oncology 2023; 25 (2): 139–49. https://doi. org/10.15407/oncology.2023.02/139/.
Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine re- duces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Ra- diat Oncol Biol Phys 2006; 64 (3): 784–91. https://doi. org/10.1016/j.ij obp.2005.06.023.
Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 2007; 12 (6): 738–47. https://doi.org/10.1634/ theoncologist.12-6-738.
Andreassen CN, Grau C, Lindegaard JC. Chemical radio- protection: a critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol 2003; 13 (1): 62–72. https://doi.org/10.1053/srao.2003.50006.
